Real-world evidence is becoming an indispensable tool for pharma companies. The availability of digital health tools, electronic health records and advances in data analytics have facilitated the large-scale collection of real-world data, enabling a wealth of insights into patient outcomes and clinical effectiveness and safety of medicines beyond clinical trials.
This Financial Times webinar will bring together global biopharma companies, health regulators, health technology assessors, and other industry experts to explore the evolving landscape for real-world evidence (RWE) in Europe, and how the regional and global evidence base can be improved and harmonised to revolutionise healthcare decision-making, drug development and patient care.
